Gastric cancer remains a significant health concern in Singapore, with approximately 500 new cases and 300 related deaths annually. Data from the Singapore Cancer Registry reveals a striking demographic pattern: the highest incidence occurs among Chinese males aged 50 and above.
Improving Overall Survival (OS) has from time past been considered the Holy Grail of cancer treatment. When discussing treatment options with patients (and referrers), oncologists often invoke the question of which modality offers the greatest survival advantage. Consequently, any treatment that does not offer an OS benefit is automatically bumped-down or relegated from the list.